Skip to main content

Alopecia Areata clinical trials at UC Irvine
4 in progress, 3 open to eligible people

  • A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

    open to eligible people ages 18-70

    This study is designed to select up to two doses of baricitinib (referred to as low dose and high dose) and assess their efficacy and safety for the treatment of severe or very severe alopecia areata.

    Irvine, California and other locations

  • Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

    open to eligible people ages 18-65

    The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.

    Irvine, California and other locations

  • PF-06651600 for the Treatment of Alopecia Areata

    open to eligible people ages 12 years and up

    This is a global Phase 2b/3 study to evaluate the safety and effectiveness of an investigational study drug (called PF-06651600) in adults and adolescents (12 years and older) who have 50% or greater scalp hair loss. The study is placebo-controlled, meaning that some patients entering the study will not receive active study drug but will receive tablets with no active ingredients (a placebo). This is a dose-ranging study, investigating 5 different dosing regimens. It will be double-blinded, meaning that the sponsor, the study doctors, the staff, and the patients will not know whether a patient is on active study drug (or the dose) or placebo.

    Irvine, California and other locations

  • Study to Evaluate the Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata

    Sorry, in progress, not accepting new patients

    This study will evaluate the safety and efficacy of CTP-543 in adult patients with chronic, moderate to severe alopecia areata.

    Irvine, California and other locations

Last updated: